Vaxcyte, Inc. Share Price

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 15/06/2024 am IST 5-day change 1st Jan Change
72.94 USD -1.45% Intraday chart for Vaxcyte, Inc. +2.78% +16.15%
Sales 2024 * - Sales 2025 * - Capitalization 7.94B 663B
Net income 2024 * -452M -37.75B Net income 2025 * -507M -42.35B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-18.2 x
P/E ratio 2025 *
-16.8 x
Employees 254
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.45%
1 week+2.78%
Current month+3.80%
1 month+1.83%
3 months+4.65%
6 months+20.44%
Current year+16.15%
More quotes
1 week
69.90
Extreme 69.9
75.70
1 month
67.21
Extreme 67.21
76.00
Current year
53.83
Extreme 53.83
82.04
1 year
44.20
Extreme 44.2
82.04
3 years
16.78
Extreme 16.78
82.04
5 years
15.51
Extreme 15.51
82.04
10 years
15.51
Extreme 15.51
82.04
More quotes
Managers TitleAgeSince
Founder 60 27/13/27
Founder 56 27/13/27
Director of Finance/CFO 55 01/20/01
Members of the board TitleAgeSince
Founder 56 27/13/27
Director/Board Member 57 16/21/16
Director/Board Member 56 01/18/01
More insiders
Date Price Change Volume
14/24/14 72.94 -1.45% 347,440
13/24/13 74.01 +0.11% 287,159
12/24/12 73.93 +1.86% 784,079
11/24/11 72.58 +0.97% 414,582
10/24/10 71.88 +1.28% 571,022

Delayed Quote Nasdaq, June 15, 2024 at 01:30 am IST

More quotes
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
72.94 USD
Average target price
103.1 USD
Spread / Average Target
+41.41%
Consensus